title: CCR4 Expression by atypical T cells in systemic pilotropic lymphoma: its behavior under treatment with interferon gamma, topical PUVA and systemic retinoid.
abstract: We describe an 88-year-old Japanese patient with pilotropic T cell lymphoma involving the peripheral blood as well as lymph nodes. This patient presented with multiple red follicular papules, confluent, infiltrated erythematous plaques and nodules. Moreover, he was conspicuous for the presence of total alopecia of the scalp and eyebrows. Histopathologically, the lesional skin showed dense follicular and perifollicular infiltrates of atypical lymphocytes. The flow cytometry disclosed the presence of weakly CD4+ CCR4+ cell populations that would not be detected in the peripheral blood from healthy controls. The patient responded well to topical PUVA and systemic etretinate (retinoid-PUVA) and intravenous IFN-gamma. Parallel with the decrease in atypical cells in the peripheral blood, the percentage of weakly CD4+ CCR4+ T cells declined. However, about 1 week after we discontinued this treatment because of the side effects, the lymph node swelling became prominent, and, 4 weeks later, the patient died before restarting any specific chemotherapy.
authors.affiliation: Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
authors.forename: Taku
authors.initials: T
authors.lastname: Fujimura
authors.forename: Setsuya
authors.initials: S
authors.lastname: Aiba
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Yoshino
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kuroki
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kimura
authors.forename: Katsuko
authors.initials: K
authors.lastname: Kikuchi
authors.forename: Takahide
authors.initials: T
authors.lastname: Kunii
authors.forename: Jun
authors.initials: J
authors.lastname: Matsunaga
authors.forename: Kouji
authors.initials: K
authors.lastname: Matsushima
authors.forename: Hachiro
authors.initials: H
authors.lastname: Tagami
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000505:Alopecia / Q000473:pathology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019742:Chemokines, CC / Q000378:metabolism; D005050:Etretinate / Q000627:therapeutic use; D005434:Flow Cytometry; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000627:therapeutic use; D008297:Male; D009182:Mycosis Fungoides / Q000188:drug therapy* / Q000378:metabolism*; D011701:PUVA Therapy; D054398:Receptors, CCR4; D019707:Receptors, Chemokine / Q000378:metabolism*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D013601:T-Lymphocytes / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; C515354:CCR4 protein, human; D019742:Chemokines, CC; D007641:Keratolytic Agents; D054398:Receptors, CCR4; D019707:Receptors, Chemokine; D005050:Etretinate; D007371:Interferon-gamma